157 related articles for article (PubMed ID: 17580262)
1. Phase I trial of parathyroid hormone to facilitate stem cell mobilization.
Ballen KK; Shpall EJ; Avigan D; Yeap BY; Fisher DC; McDermott K; Dey BR; Attar E; McAfee S; Konopleva M; Antin JH; Spitzer TR
Biol Blood Marrow Transplant; 2007 Jul; 13(7):838-43. PubMed ID: 17580262
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma.
Kroschinsky F; Hölig K; Platzbecker U; Poppe-Thiede K; Ordemann R; Blechschmidt M; Oelschlaegel U; Schaich M; Hänel M; Bornhäuser M; Ehninger G
Transfusion; 2006 Aug; 46(8):1417-23. PubMed ID: 16934080
[TBL] [Abstract][Full Text] [Related]
3. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
4. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S
Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420
[TBL] [Abstract][Full Text] [Related]
5. Ancestim (recombinant human stem cell factor, SCF) in association with filgrastim does not enhance chemotherapy and/or growth factor-induced peripheral blood progenitor cell (PBPC) mobilization in patients with a prior insufficient PBPC collection.
da Silva MG; Pimentel P; Carvalhais A; Barbosa I; Machado A; Campilho F; Sousa SR; Miranda N; da Costa FL; Campos A; Vaz CP; Antas J; Passos-Coelho JL
Bone Marrow Transplant; 2004 Oct; 34(8):683-91. PubMed ID: 15322567
[TBL] [Abstract][Full Text] [Related]
6. Utilization study of filgrastim (Neutromax) during autologous haematopoietic precursor transplantation for myeloma and lymphoma patients.
Ferro HH; Juni M; Bello R; Vidal A; Diez RA; Pavlovsky S
Transfus Apher Sci; 2009 Oct; 41(2):87-93. PubMed ID: 19699152
[TBL] [Abstract][Full Text] [Related]
7. Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim.
To LB; Bashford J; Durrant S; MacMillan J; Schwarer AP; Prince HM; Gibson J; Lewis I; Swart B; Marty J; Rawling T; Ashman L; Charles S; Cohen B
Bone Marrow Transplant; 2003 Mar; 31(5):371-8. PubMed ID: 12634728
[TBL] [Abstract][Full Text] [Related]
8. The role of pegfilgrastim in mobilization of hematopoietic stem cells.
Kroschinsky F; Hölig K; Ehninger G
Transfus Apher Sci; 2008 Jun; 38(3):237-44. PubMed ID: 18490197
[TBL] [Abstract][Full Text] [Related]
9. Pegfilgrastim effectively mobilizes PBSC in a poor mobilizer multiple myeloma patient.
Malerba L; Mele A; Leopardi G; Stramigioli S; Politi P; Visani G
Eur J Haematol; 2006 May; 76(5):436-9. PubMed ID: 16480428
[TBL] [Abstract][Full Text] [Related]
10. Pegfilgrastim for peripheral CD34+ mobilization in patients with solid tumours.
Willis F; Woll P; Theti D; Jamali H; Bacon P; Baker N; Pettengell R
Bone Marrow Transplant; 2009 Jun; 43(12):927-34. PubMed ID: 19169289
[TBL] [Abstract][Full Text] [Related]
11. Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma.
Tomblyn M; Burns LJ; Blazar B; Wagner J; Lee C; Rogers T; McGlave P; Miller JS; Weisdorf DJ
Bone Marrow Transplant; 2007 Jul; 40(2):111-8. PubMed ID: 17530003
[TBL] [Abstract][Full Text] [Related]
12. Single-dose pegfilgrastim is comparable to daily filgrastim in mobilizing peripheral blood stem cells: a case-matched study in patients with lymphoproliferative malignancies.
Putkonen M; Rauhala A; Pelliniemi TT; Remes K
Ann Hematol; 2009 Jul; 88(7):673-80. PubMed ID: 19139894
[TBL] [Abstract][Full Text] [Related]
13. Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial.
Gupta S; Zhou P; Hassoun H; Kewalramani T; Reich L; Costello S; Drake L; Klimek V; Dhodapkar M; Teruya-Feldstein J; Hedvat C; Kalakonda N; Fleisher M; Filippa D; Qin J; Nimer SD; Comenzo RL
Bone Marrow Transplant; 2005 Mar; 35(5):441-7. PubMed ID: 15640822
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Russell N; Mesters R; Schubert J; Boogaerts M; Johnsen HE; Canizo CD; Baker N; Barker P; Skacel T; Schmitz N
Haematologica; 2008 Mar; 93(3):405-12. PubMed ID: 18268285
[TBL] [Abstract][Full Text] [Related]
15. Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma.
Nakasone H; Kanda Y; Ueda T; Matsumoto K; Shimizu N; Minami J; Sakai R; Hagihara M; Yokota A; Oshima K; Tsukada Y; Tachibana T; Nakaseko C; Fujisawa S; Yano S; Fujita H; Takahashi S; Kanamori H; Okamoto S;
Am J Hematol; 2009 Dec; 84(12):809-14. PubMed ID: 19862826
[TBL] [Abstract][Full Text] [Related]
16. The role of diagnosis in patients failing peripheral blood progenitor cell mobilization.
Koenigsmann M; Jentsch-Ullrich K; Mohren M; Becker E; Heim M; Franke A
Transfusion; 2004 May; 44(5):777-84. PubMed ID: 15104662
[TBL] [Abstract][Full Text] [Related]
17. Parathyroid hormone effectively induces mobilization of progenitor cells without depletion of bone marrow.
Brunner S; Zaruba MM; Huber B; David R; Vallaster M; Assmann G; Mueller-Hoecker J; Franz WM
Exp Hematol; 2008 Sep; 36(9):1157-66. PubMed ID: 18504066
[TBL] [Abstract][Full Text] [Related]
18. Targeting the stem cell niche: squeezing blood from bones.
Ballen K
Bone Marrow Transplant; 2007 Jun; 39(11):655-60. PubMed ID: 17401397
[TBL] [Abstract][Full Text] [Related]
19. Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma.
Hosing C; Qazilbash MH; Kebriaei P; Giralt S; Davis MS; Popat U; Anderlini P; Shpall EJ; McMannis J; Körbling M; Champlin RE
Br J Haematol; 2006 Jun; 133(5):533-7. PubMed ID: 16681642
[TBL] [Abstract][Full Text] [Related]
20. DCEP chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients.
Zappasodi P; Nosari AM; Astori C; Ciapanna D; Bonfichi M; Varettoni M; Mangiacavalli S; Morra E; Lazzarino M; Corso A
Transfusion; 2008 May; 48(5):857-60. PubMed ID: 18248573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
